|Bid||3.0000 x 1300|
|Ask||3.0200 x 900|
|Day's Range||3.0000 - 3.0500|
|52 Week Range||2.1500 - 3.6900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 13, 2020 - Apr 19, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
Biomerica, Inc. (BMRA) today reported net sales of $1,596,408 for the three months ended November 30, 2019, compared to $1,500,791 for the same period in the previous year, an increase of 6.4%. Biomerica announced a net loss for the three months ended November 30, 2019 of $485,260, or $0.05 per share, versus a net loss of $477,244, or $0.05 per share, in the previous fiscal year during the same quarter. The net loss for the six months ended November 30, 2019 was $991,556, or $0.10 per share, compared to net loss of $928,984, or $0.10 per share in the prior fiscal year.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
IRVINE, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that Houston Methodist (part of Texas Medical Center, the largest medical complex in the world) will start enrollment for the clinical trial of its new InFoods® diagnostic-guided therapy (DGT) to alleviate Irritable Bowel Syndrome (IBS) symptoms. Houston Methodist will join Beth Israel Deaconess Medical Center Inc., a Harvard Medical School Teaching Hospital, and the University of Michigan as primary enrollment centers for this study.
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares...
A look at the shareholders of Biomerica, Inc. (NASDAQ:BMRA) can tell us which group is most powerful. Large companies...
Biomerica, Inc. (BMRA) today reported net sales of $1,194,415 for the three months ending August 31, 2019, compared to $1,272,870 for the same period in the previous year. “Although revenues in Q1 2020 were slightly lower than the prior year, we expect sales of our specialty diagnostics to begin increasing in Q2, as compared to the same quarterly sales in the previous year," said Zackary Irani, CEO of Biomerica, Inc. “We also expect to be near completion of the enrollment of patients for clinical trials for our H. Pylori diagnostic product in fiscal Q2 and plan to submit to the FDA shortly thereafter. Further, during Q2 we plan to announce important progress in the clinical trials for our diagnostic guided therapy, InFoods® technology, which we expect to make a significant impact on some of the 45 million Americans who suffer from Irritable Bowel Syndrome (IBS).
Zackary Irani has been the CEO of Biomerica, Inc. (NASDAQ:BMRA) since 1997. This analysis aims first to contrast CEO...
Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...
Anyone researching Biomerica, Inc. (NASDAQ:BMRA) might want to consider the historical volatility of the share price...
Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682 versus net sales of $5,564,185 in fiscal 2018. This initial U.S. patent covers the Company’s InFoods® family of products that allow for revolutionary new treatment options for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases.
IRVINE, Calif., Aug. 21, 2019 -- Biomerica, Inc. (Nasdaq: BMRA) announced the Republic of Colombia Ministry of Health and Social Protection Institute National Surveillance of.
It hasn't been the best quarter for Biomerica, Inc. (NASDAQ:BMRA) shareholders, since the share price has fallen 11...
MaxHealth to distribute Biomerica’s colorectal screening test to help identify the early warning signs of colorectal cancer. IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million over the initial seven year term and further requires an upfront pre-payment of $1 million after meeting certain conditions.
Biomerica (BMRA) reported financial results for their fiscal 2019 third quarter ending February 28, 2019. Revenue has decreased each of the first three quarters of 2019 as compared to the respective prior-year periods and through the first nine months, is down 9% from 2018. Revenue through the first nine months from each of three most significant territories is down from last year.
Biomerica, Inc. (BMRA) today reported net sales of $4,034,822 for the nine months ending February 28, 2019, compared to $4,433,785 for the period ended February 28, 2018. Sales for the three months ending February 28, 2019 were $1,261,161 compared to $1,375,666 for the period ended February 28, 2018. In addition, the Company announced progress in both its InFoods® IBS clinical study and H. pylori study as well as the issuance of its first patent pertaining to the Company’s InFoods® family of products that are designed to allow for a revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. “We are very pleased that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products. The patent validates the unique InFoods product which is designed to allow physicians to offer new and better therapies to patients.
Biomerica, Inc. (BMRA) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biomerica’s first U.S. patent pertaining to the Company’s InFoods® family of products that allow for revolutionary new treatment option for patients suffering from Irritable Bowel Syndrome (IBS) and other gastrointestinal diseases. Specifically, this allowed application (#15/526,240) contains numerous claims that broadly cover a product that enables physicians to identify patient specific foods (e.g.
LOS ANGELES, CA / ACCESSWIRE / March 12 , 2019 / LD Micro, a company that puts on conferences for micro-cap and small-cap companies will be hosting 46 companies on March 12th (that's today) and 13th, starting ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Anyone researching Biomerica, Inc. (NASDAQ:BMRA) might want to consider theRead More...
Based on recent discussions between Biomerica and the United States Food and Drug Administration (FDA) regarding the regulatory pathway for final FDA clearance of the Company’s H. pylori product, the Company needs less than 40 clinical trial patient samples in addition to the 210 samples already collected. These final clinical patient samples are expected to be collected over the next few months, after which the Company will complete the remaining analytical and clinical agreement studies and prepare a submission to the FDA for 510(k) FDA clearance. Helicobacter pylori (H. pylori) infection is one of the most common, chronic, bacterial infections affecting humans. Complications associated with H. pylori infections include ulcers, inflammation of the stomach lining and stomach cancer. The diagnosis of H. pylori is important given that specific antibiotic treatment is highly effective in improving outcomes.